SLIT: Implementation in Your Practice
Now that the FDA has approved the first sublingual immunotherapy (SLIT) products for use in the United States, allergist/immunologists have new options to consider when treating their patients who could benefit from allergen immunotherapy. This presentation - a recording of a symposium presented at the 2014 AAAAI Annual Meeting - provides an overview of the mechanisms of SLIT, a summary of the results of clinical trials with these new forms of immunotherapy, and a discussion of how to incorporate the administration of SLIT into an allergy/immunology practice.
Allied Health Professionals working in allergy/immunology practices
- Review how SLIT works.
- Discuss the results of pivotal SLIT clinical trials.
- Describe how to use SLIT in practice.
Desiree E.S. Larenas-Linnemann, MD FAAAAI
Michael S. Tankersley, MD FAAAAI
Stephen R. Durham, MA MD FRCP
Thomas B. Casale, MD FAAAAI
Linda Cox, MD FAAAAI
- 1.25 AttendanceAttendance credit.
- 1.50 CECE credit.
- 1.25 CMECME credit.